IO+ADC战局悬念再起

药闻社
Jan 17

点击上面“蓝字”关注我们!本文来源于深蓝观;如果喜欢,欢迎在文末处点个“在看”,感谢您的支持!近期,围绕PD-1/VEGF双抗的消息接连不断。1月12日,荣昌生物宣布与艾伯维就PD-1/VEGF双抗药物RC148签署独家授权许可协议;1月13日,辉瑞在JPM医疗健康大会上宣布,同类药物SSGJ-707将于2026年内开展四类肿瘤疾病的三期临床试验,均为一线治疗。同日, Summit宣布已向FDA...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10